Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 28.35B +1.9% |
| Revenue (ttm) | 3.25B +82.6% |
| Net Income | 407.42M |
| EPS | 2.99 |
| Shares Out | n/a |
| PE Ratio | 69.59 |
| Forward PE | 25.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 292.00 |
| Previous Close | 301.00 |
| Day's Range | 285.18 - 301.98 |
| 52-Week Range | 282.58 - 500.21 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections and auditor ratification. Strong financial results were highlighted, with Q1 product revenue up 121% year-over-year and ambitious growth and innovation targets set through 2030.
Alnylam Issues 2025 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The...
Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is leveraging its RNAi platform to drive profitable growth, with strong AMVUTTRA sales and ambitious 2026 guidance. Pipeline investments focus on next-generation TTR therapies and new indications, while robust cash reserves support both internal and external innovation.
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in pa...
Alnylam to Webcast Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients wit...
Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw record net product revenues exceeding $1 billion, driven by robust TTR franchise growth and strong rare disease performance. The company reiterated full-year guidance, advanced its pipeline, and maintained high gross margins despite royalty headwinds.
Alnylam Pharmaceuticals Quarterly report: Q1 2026
Alnylam Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 30, 2026.
Alnylam Pharmaceuticals Slides: Q1 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Alnylam Pharmaceuticals Earnings release: Q1 2026
Alnylam Pharmaceuticals released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...
Alnylam Pharmaceuticals Proxy statement: Proxy filing
Alnylam Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Alnylam Pharmaceuticals Proxy statement: Proxy filing
Alnylam Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) po...
Alnylam Pharmaceuticals Transcript: Status update
AMVUTTRA has rapidly gained market share in ATTR cardiomyopathy, driving strong revenue growth and broad physician adoption. Clinical data support its differentiated profile, while strategic investments in diagnosis, access, and innovation position it for sustained leadership and expansion globally.
Alnylam Pharmaceuticals Press release: Status update
Alnylam Pharmaceuticals issued a press release on March 24, 2026, disclosing material business information to investors.
Alnylam Pharmaceuticals Slides: Status update
Alnylam Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutic...
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recogn...
How Alnylam Stock Weathers Market Shocks
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experience...
Alnylam to Webcast TTR Investor Webinar
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the In...
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill...